MNTL TEMA NEUROSCIENCE AND MENTAL HEALTH ETF
- 24.375
- -0.020-0.08%
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 20 Years
Live Stock News: -2.8% GDP, Trade War Sends Market Lower, Tesla Sales Punished
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
Here's How Much $100 Invested In Stryker 15 Years Ago Would Be Worth Today
Live Stock News: Chips Falling Alongside Crypto Despite Trump Money News-- the Honeymoon is Over
Eli Lilly's Options Frenzy: What You Need to Know
Play Defense With Goldman's Cheap Healthcare Picks
Notable Healthcare Headlines for the Week: Viatris, J&J, Walgreens Boots Alliance Teladoc Health and Pfizer in Focus
Wall Street Today: Market Ends Wild Political TV Day in the Green
Earnings Call Summary | Crinetics(CRNX.US) Q4 2024 Earnings Conference
Oppenheimer Maintains Outperform on Argenx, Raises Price Target to $704
Wells Fargo Maintains Overweight on Argenx, Raises Price Target to $741
4 Stocks to Watch on Friday: FUBO, ADSK, META and LLY
Biogen, Eisai Alzheimer's Drug Sent Back for EU Nod After Safety Review
The CHMP Reaffirms Positive Opinion For Lecanemab In Early Alzheimer's Disease
Lilly's Jaypirca Recommended By CHMP For Approval In The EU For Adults With Relapsed Or Refractory Chronic Lymphocytic Leukemia Previously Treated With A BTK Inhibitor
Eli Lilly in Pact With Magnet Bio to Develop Cancer Drugs in a Deal Worth up to $1.25B
Argenx Analyst Ratings
Neurocrine Biosciences Reports Patient-Reported Outcome Data From The KINECT-PRO Study Of INGREZZA; Says 'Results Showed Significant and Sustained Improvements From Baseline in All Three Patient-reported Outcome Measures,'